Rimidi and ARKRAY Partner to Bring Glucose Data to the EHR

Rimidi and ARKRAY Partner to Bring Glucose Data to the EHR

Posted May 9, 2022 from

Rimidi announced its integration with the ARKRAY GLUCOCARD® Shine Connex Blood Glucose Monitoring System to Rimidi’s Platform.

What You Should Know:

– In an effort to make blood glucose data more actionable for providers and patients alike, Rimidi, a leading clinical management platform announced its integration with the ARKRAY GLUCOCARD® Shine Connex Blood Glucose Monitoring System to Rimidi’s Platform.

– The integration enables providers to manage blood-glucose control more proactively within existing workflows, thus boosting patient adherence.

Diabetes is the most expensive chronic condition in the nation, with more than $237 billion spent each year on direct medical costs, and another $90 billion on reduced productivity. With over 37 million people in the U.S. currently living with the condition, patients must have access to reliable and affordable blood glucose monitoring systems. The integration between Rimidi and ARKRAY enables providers to see blood glucose data in their EHR existing workflows, thus providing a more comprehensive view of patients’ health, and in turn driving better clinical decisions. For example, providers are alerted when a patient has an out-of-range reading or has not taken their blood-glucose in a certain amount of time, prompting them to follow up with their patient accordingly.


Rimidi Inc.

Rimidi Inc.

Rimidi is a group of healthcare entrepreneurs aligned in a belief that we can do so much better-as individuals, and as an industry-in providing significant and enduring solutions. Our leadership team is comprised of physicians, bioengineers and business professionals credited with developing technologies and practices successfully used in healthcare today.



Did you find this useful? Like

See Topics


Related Offerings

See Also

Next Article